Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter, ...
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors? We'll ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback